

Special Issue

State-of-the-Art and Novel Approaches in Molecular and Translational Medicine in Europe

Message from the Guest Editor

The rapid advancement of technology has led to the establishment of high throughput and state-of-the-art techniques that benefit biomedicine research. There is a growing interest in unraveling the mechanistic basis of pathophysiological backgrounds, identifying accurate and easy-to-detect biomarkers, and finding novel promising therapies through the use of omics technologies, bioinformatics analyses, and other technological breakthroughs. In this Special Issue, European experts in the field of biomedicine are invited to present the progress of translational medicine in our continent through the use of novel or state-of-the-art approaches in the fields of molecular, cellular, and biochemical medicine. These approaches may include high throughput techniques, in vitro and in vivo models of disease/physiology, bioinformatic tools and novel therapeutics, as well as unique approaches for studying biomedical issues.

Guest Editor

Dr. Vasileios Tzounakas

Department of Biochemistry, School of Medicine, University of Patras, Patras, Greece

Deadline for manuscript submissions

closed (15 January 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/110077

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).